Compare · ABBV vs TVRD
ABBV vs TVRD
Side-by-side comparison of AbbVie Inc. (ABBV) and Tvardi Therapeutics Inc. (TVRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and TVRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $505.89B, about 38396.6x TVRD ($13.2M).
- ABBV has been more active in the news (8 items in the past 4 weeks vs 5 for TVRD).
- ABBV has more recent analyst coverage (25 ratings vs 15 for TVRD).
- Company
- AbbVie Inc.
- Tvardi Therapeutics Inc.
- Price
- -
- -
- Market cap
- $505.89B
- $13.2M
- 1M return
- +0.52%
- -
- 1Y return
- +24.79%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2014
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 15
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
- EVP, CHIEF OPERATIONS OFFICER Azita Saleki exercised 23,935 shares at a strike of $61.36 and covered exercise/tax liability with 13,481 shares, increasing direct ownership by 5% to 208,248 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
Latest TVRD
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
- SEC Form 10-Q filed by Tvardi Therapeutics Inc.
- Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
- Chardan Capital Markets initiated coverage on Tvardi Therapeutics with a new price target
- Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
- New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
- Tvardi Therapeutics to Participate in Upcoming Investor Events
- SEC Form 10-Q filed by Tvardi Therapeutics Inc.